Funded Biotechnology Startups
The 20 most recent funded biotechnology, pharmaceuticals, and healthcare companies span late September through late November 2025, with activity concentrat…
The 20 most recent funded biotechnology, pharmaceuticals, and healthcare companies span late September through late November 2025, with activity concentrated in the United States and China. US-based companies account for 9 of the 20 entries; the largest disclosed US rounds are Crystalys Therapeutics in San Diego ($205M Series A), Solve Therapeutics in Belmont ($120M), and TORL BioTherapeutics in Culver City ($96M Series C). China contributes five companies across Minhang, Suzhou, Hangzhou, Pudong, and Shanghai, though several—including UniXell Biotechnology and Gaowei Medicine—closed rounds with undisclosed amounts.
Series A is the most represented labeled stage, appearing in six of the 20 rounds. Five rounds carried no disclosed dollar figure, and one—BOOST Pharma in Copenhagen—used a convertible note structure. Outside the US and China, Edinburgh-based Trogenix raised $94M in a Series A, and Paris-based Step Pharma closed a $44M Series C in mid-October.
Most recent rounds
20 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Crystalys Therapeutics (San Diego) leads at $205M on a Series A closed October 4. Solve Therapeutics (Belmont) raised $120M in a Venture - Series Unknown round on November 21, and TORL BioTherapeutics (Culver City) closed a $96M Series C on October 12. Trogenix (Edinburgh) and Neok Bio (Palo Alto) also exceeded $75M, at $94M and $75M respectively, both Series A rounds.
Where are most of these companies headquartered?
Nine of the 20 companies are US-based, spread across San Diego, Palo Alto, Boston, Belmont, New York, Culver City, Blue Bell, and Burlington—the last appearing twice, for Lifordi Immunotherapeutics and SQ Innovation. China is the second most represented country with five companies in Minhang, Suzhou, Hangzhou, Pudong, and Shanghai.
Which funding stage appears most often in this group?
Series A is the most represented labeled stage, with six companies: Waker Biology, Kunshi Biotechnology, Neok Bio, UniXell Biotechnology, Trogenix, and Crystalys Therapeutics. Four additional rounds are categorized as Venture - Series Unknown, meaning the series letter was not publicly disclosed at the time of the round.
How many of these rounds have undisclosed funding amounts?
Five of the 20 rounds closed without a disclosed dollar figure: Imbria Pharmaceuticals (Series B, Boston), Gaowei Medicine (Seed, Hangzhou), Lysin Bio (Seed, Daejeon), UniXell Biotechnology (Series A, Pudong), and SQ Innovation (Series B, Burlington). Undisclosed amounts span seed through Series B, so the pattern is not limited to early-stage companies.
Which countries outside the US and China are represented?
Five companies with known locations are headquartered outside the US and China: Trogenix (Edinburgh, UK, $94M Series A), Step Pharma (Paris, $44M Series C), BOOST Pharma (Copenhagen, $2M convertible note), Twinpig Biolab (Seoul, $1M), and Lysin Bio (Daejeon, undisclosed seed). Aerska, which raised $21M in a seed round on September 29, has no location listed in the data.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.